Pharmacologic, biologic, and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity

Transplantation

Volumn 75, Issue 9 SUPPL., 2003, Pages

  Coates, P Toby H ^a   Colvin, Bridget L ^a,b   Kaneko, Katsuhiko ^a   Taner, Timucin ^a,b   Thomson, Angus W ^a,b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ACETYLSALICYLIC ACID; ANTIMETABOLITE; CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; COLECALCIFEROL; CORTICOSTEROID; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOUBLE STRANDED DNA; HLA B7 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; OKT 4; OLIGODEOXYNUCLEOTIDE; RAPAMYCIN; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

BIOLOGICAL THERAPY; CELL MATURATION; CELL SUBPOPULATION; CONFERENCE PAPER; DENDRITIC CELL; DRUG MECHANISM; EXPERIMENTAL MODEL; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ENGINEERING; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE MIGRATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; TRANSPLANTATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BIOLOGICAL PRODUCTS; CELL AGING; CELL MOVEMENT; DENDRITIC CELLS; GENETIC ENGINEERING; HUMANS; PHARMACOLOGY; TRANSPLANTATION TOLERANCE;

EID: 0037846483     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Coates PTH, Colvin BL, Hackstein H, et al. Manipulation of dendritic cells as an approach to improved outcomes in transplantation. Exp Rev Mol Med [serial online]. 2002; Feb 18. http://www.ermm.cbcu.cam.ac.uk/02004283h.htm.
2. Hackstein H, Taner T, Zahorchak AF, et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic sell mobilization and function in vivo. Blood 2003 (in press).
3. Hackstein H, Taner T, Logar AJ, et al. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084.
4. Lu L, Thomson AW. Genetic engineering of dendritic cells to enhance their tolerogenic potential. Graft 2002; 5: 308.
5. Min WP, Gorczynski R, Huang XY, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000; 164(1): 161.
6. Matsue H, Matsue K, Walters M, et al. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat Med 1999; 5(8): 930.
7. Takayama T, Nishioka Y, Lu L, et al. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998; 66(12): 1567.
8. Takayama T, Morelli AE, Robbins PD, et al. Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro. Gene Ther 2000; 7(15): 1265.
9. Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107(10): 1275.
10. Kim SH, Kim S, Evans CH, et al. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001; 166(5): 3499.
11. Giannoukakis N, Bonham CA, Qian S, et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther 2000; 1(5 pt 1): 430.
12. Fairchild RL, Kobayashi H, Miura M. Chemokines and the recruitment of inflammatory infiltrates into allografts. Graft 2000; 3(suppl 1): S24.
13. Nelson PJ, Krensky AM. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001; 14(4): 377.
14. Colvin BL, Thomson AW. Chemokines, their receptors, and transplant outcome. Transplantation 2002; 74: 149.
15. O'Connell PJ, Li W, Wang Z, et al. Immature and mature CD8α+ dendritic cells prolong the survival of vascularized heart allografts. J Immunol 2002; 168(1): 143.
16. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193(2): 233.
17. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192(9): 1213.
18. Arpinati M, Green CL, Heimfeld S, et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95(8): 2484.
19. Coates PTH, Barratt-Boyes SM, Zhang L, et al. Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with FLT3 ligand. Blood 2003 (in press).